101
|
|
|
Recombination activating 2 |
RAG-2 |
Experimental arthritis, Combined cellular and humoral immune defects with granulomas, Combined immunodeficiency with granulomatosis, Combined immunodeficiency with skin granulomas, Common variable immunodeficiency, Eosinophilia, Immunodeficiency, Nonalcoholic fatty liver disease, Omenn syndrome, Salla disease, Severe combined immunodeficiency |
102
|
|
|
Retinoic acid induced 1 |
SMCR, SMS |
17p11.2 microduplication syndrome, Anxiety disorder, Attention deficit hyperactivity disorder, Autism, Basal cell carcinoma, Coronary artery disease, Craniofacial abnormalities, Deafness, Developmental disability, Glioma, Growth disorder, Intellectual developmental disorder, Melanoma, Myocardial infarction, Neurodevelopmental disorder, Obesity, Obsessive-compulsive disorder, Potocki-lupski syndrome, Prostate cancer, Psychiatric disorders, Schizophrenia, Smith-magenis syndrome, Diabetes mellitus type 2View all (8 more) |
103
|
|
|
Retinoic acid induced 14 |
NORPEG, RAI13 |
|
104
|
|
|
Retinoic acid induced 2 |
- |
|
105
|
|
|
RAS like proto-oncogene A |
HINCONS, RAL |
|
106
|
|
|
RAS like proto-oncogene B |
- |
|
107
|
|
|
RalA binding protein 1 |
RIP1, RLIP1, RLIP76 |
|
108
|
|
|
Ral GTPase activating protein catalytic subunit alpha 1 |
GARNL1, GRIPE, NEDHRIT, RalGAPalpha1, TULIP1, p240 |
|
109
|
|
|
Ral GTPase activating protein catalytic subunit alpha 2 |
AS250, C20orf74, bA287B20.1, dJ1049G11, dJ1049G11.4, p220 |
|
110
|
|
|
Ral GTPase activating protein non-catalytic subunit beta |
KIAA1219, RalGAPbeta |
|